Go to
JCI Insight
About
Editors
Consulting Editors
For authors
Publication ethics
Publication alerts by email
Advertising
Job board
Contact
Clinical Research and Public Health
Current issue
Past issues
By specialty
COVID-19
Cardiology
Gastroenterology
Immunology
Metabolism
Nephrology
Neuroscience
Oncology
Pulmonology
Vascular biology
All ...
Videos
Conversations with Giants in Medicine
Video Abstracts
Reviews
Reviews
View all reviews ...
Review Series
Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
Microbiome in Health and Disease (Feb 2025)
Substance Use Disorders (Oct 2024)
Clonal Hematopoiesis (Oct 2024)
Sex Differences in Medicine (Sep 2024)
Vascular Malformations (Apr 2024)
Lung inflammatory injury and tissue repair (Jul 2023)
View all review series ...
Viewpoint
Collections
In-Press Preview
Clinical Research and Public Health
Research Letters
Letters to the Editor
Editorials
Commentaries
Editor's notes
Reviews
Viewpoints
100th anniversary
Top read articles
Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies.
/articles/view/114952C1
Published February 1, 1991
Citation Information:
J Clin Invest.
1991;
87(2)
:757-757.
https://doi.org/10.1172/JCI114952C1
.
View:
Text
|
PDF
|
Amended Article
Correction
Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies.
Text
PDF
Abstract
Authors
×
Full Text PDF
Download PDF
(53.03 KB)
